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The effects of exogenous prostaglandin El (PGE,) or prostaglandin E2 (PGE2) were studied in the
isolated perfused rat liver and in the intact canine liver in order to determine the possible physiological role
of prostaglandins on hepatic carbohydrate and lipid metabolism. The data indicate that PGEI and PGE, did
not stimulate cyclic AMP (cAMP) and cyclic GMP (cGMP) concentrations in intact dog liver and PGE,
failed to stimulate cAMP orcGMP infed orfasted perfused rat liver. PGE, did not promotehyperglycemia,
glycogenolysis, lipolysis, or prevent epinephrine-induced hyperglycemia in the isolated perfused rat liver.
Other known glycogenolytic agentsincludingglucagon and epinephrine increased cAMP andglycogenolysis
in the same perfusion system. This study does not support a physiologic role for PGE, on hepatic
glycogenolysis or lipolysis. If PGE, subsequently is found to influence other metabolic parameters such as
lipogenesis, gluconeogenesis, ureogenesis or amino acid transport in isolated perfused liver, such alterations
would probably occur independent of changes in cyclic nucleotide activity.
INTRODUCTION
Our prior studies in isolated perfused rat liver demonstrated the effect of cyclic
AMP (cAMP), glucagon, epinephrine and serotonin or its endogenous precursor, 5-
hydroxytryptophan, on glycogen metabolism [1,2]. These agents produced glycogen-
olysis, hyperglycemia, and stimulation of hepatic phosphorylase activity in isolated
perfused rat liver [1,2]. The glycemic effect of serotonin observed in vitro was also
noted in vivo. Serotonin may produce these physiological actions by activation of
hepatic cAMP concentrations [1].
There is increasing evidence to show that E-type prostaglandins regulateintracellu-
lar cAMP levels but their complex interrelationships have not been clarified. It
remains unclear whether the prostaglandin effect is related solelyto adenylate cyclase
activity or alteration in phosphodiesterase, adenylate kinase [3], and ATPase.
Although prostaglandins are rapidly metabolized by the liver, there is conflicting
data regarding their specific actions on hepatic carbohydrate and lipid metabolism or
on the adenylate cyclase-cAMP system in vitro or in vivo. In vitro experiments in
adipose tissue demonstrate that prostaglandin El (PGE1) stimulates glucose uptake,
glucose oxidation, and glycogen and triglyceride synthesis from labeled glucose [4].
Adenylate cyclase is stimulated in liver broken-cell homogenates from rat, mouse,
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rabbit, and dog by PGE1 in the presence of purine nucleotides, including guanosine
triphosphate [5,6]. PGE, alone also increased adenylate cyclase activity in liver
homogenates and in isolated rat liver cells [7-11]. Curnow and Nuttall [12] observed
that PGE, decreased hepatic glycogen synthetase without altering glycogen concen-
trations. This change is compatible with increased hepatic cAMP and suggested
possible direct effects on hepatic glycogen levels. Nevertheless, the actions of
prostaglandins on glucose metabolism are variable. PGE, has been reported to cause
hyperglycemia [13-15] or to inhibit glucose metabolism in liver [16].
Prior studies have not clarified the possible in situ role of PGEI on hepatic
glycogenolysis. Exton et al. [17] concluded that PGE, perfusion in rat liver failed to
alter cAMP levels or glucose production but detailed results were never presented.
Others have reported a glycogenolytic effect of PGE, in rat liver slices [18]. In
perfused rat liver a variable effect was noted in fed and fasted animals by Wilson and
Handewych [19]. Only in the fasted state could they observe PGE I-induced glycogen-
olysis. Zenser et al. have shown transient modest increases in cAMP in perfused rat
liver 1 to 3 min after PGE, administration [10]. There is only a single published
report concerning the effects of PGE, on gluconeogenesis in perfused rat liver [20].
This study showed that PGE, inhibited gluconeogenesis, possibly between the
glycerol and glucose steps [20].
Since notable species differences have been found in the hepatic adenylate cyclase-
cAMP response to prostaglandins, we have investigated the possible interaction of
prostaglandins on hepatic cyclic nucleotide concentration in both rats and dogs.
There are no published data on the hepatic cyclic GMP (cGMP) concentration after
treatment with prostaglandins. Thus we have studied the response of this nucleotide
to 2 types of E prostaglandins, PGE, and prostaglandin E2 (PGE2). We also have
evaluated the effects of PGE, on hepatic glycogenolysis, and lipolysis. These studies
extend out preliminary report [21].
METHODS
The effects of PGE, or PGE2 were studied in the isolated perfused rat liver (3.3
,ug/min) and in the intact canine liver (25,g/kg bolus then 20u jg/min). Because
PGE I and PGE2 are rapidly metabolized by the liver and most ofit removed during a
single passage, they were administered continuously [22].
The effects ofPGE, in isolated perfused rat liver bn both liver and perfusate cAMP
content were compared to that induced by dibutyryl cAMP (DBC), glucagon,
epinephrine, and a control infusion of a Ringer solution containing an appropriate
amount of ethanol added to the perfusion. Ethanol was used as a control since
ethanol is used as a diluent of PGEI, since extremely small amounts of ethanol can
influence carbohydrate and lipid metabolism in the perfused liver, and since certain
short chain alcohols, including ethanol, have been shown to activate adenylate
cyclase in vitro [23,24].
Isolated male fed or fasted donor Sprague-Dawley rat livers (mean body weight
297 ± (S.E.M.) 25 g, mean liver weight = 6.4 ± 1.8 g) were perfused with 85 ml Krebs-
Ringer bicarbonate solution containing 3% albumin and 0.95% ethanol, as previously
described [25]. Samples of perfusate glucose, cAMP, cGMP and free fatty acids
(FFA), hepatic glycogen, triglyceride (TG), and cAMP, and bile weretakenduring a
control period of 45 min and at 2, 3, 5, 10, 15, 30, or 60 min intervals and after
exposure to PGEI, epinephrine, glucagon, or DBC (see Table 1 for concentrations
'Kindly supplied by J.E. Pike, The Upjohn Company, Kalamazoo, Michigan.
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TABLE I
Isolated Perfused Red Rat Liver Increment Change (0-60 Min)
(Mean + S.E.M.)
Perfusate Liver
Glucose cAMP Glycogen TG cAMP
Compound No. Dose/hr (mg/100 ml) (pmol/ml) (mg/g) (mg/g) (pmol/ml)
Ringer-ETOH 9 0.25% +68 * 12 -8 * 6 -8 i 3 -I * 3 -65 i 18
PGE 9 100-200,g +55 * 14 +13±8 -6*2 -1 i1 -103±26
Epinephrine 4 100Mug +182 i 5 +14 * 5 -18 i 4 a - +283* 25a.b
Glucagon 4 100-200i'g +223 i28a +18 i 4 -26 i 6a - +1490 i 280a
DBC 4 2 mg +320 i 68a - -30 i 7 a
ap<0.05
b30 min value
used). Since PGE, may influence some ofthe metabolic effects of catacholamines in
certain other tissues, the possible interaction betweenepinephrine and PGE1 was also
studied in the perfusion experiments.
Studies in the 18 hour-fasted intact canine liver were carried out using direct
intraarterial infusion of PGE,, PGE2, or indomethacin, a prostaglandin synthetase
inhibitor (5 mg/kg for 5 min then 5 mg/min), into the hepatic artery via a catheter
placed in the celiac axis. All studies were done in the acute dog anesthetized with
intravenous sodium pentobarbital, 30 mg/kg. Infusions were given after a 30 min
control period with saline or indomethacin. Approximately 25% of the infused
radiopaque agent went directly into the hepatic artery, the remainder into the arterial
blood supply to the stomach. Samples of dog liver were obtained for cAMP and
cGMP at frequent intervals during a 30 min exposure to exogenous PGE, or PGE2
or indomethacin.
cAMP and cGMP were measured by radioimmunoassay [26]. Other biochemical
determinations were performed as described [25] or by standard techniques. All
results are given as mean ± S.E.M. and were compared using the Student's t test for
mean differences of paired samples.
RESULTS
During the 45 min period of equilibration there was a moderate uptake of fat as
determined by, a fall in perfusate FFA. Heparinization during the removal of fed
donor livers accounted for initially higher levels of FFA. However, during the study
period, PGE1 failed to alter FFA orcAMP levels intheperfusate, bileflow orinduce
hyperglycemia compared to control perfusions (Fig. 1).
That this system responded to knownglycogenolytic agents which increase hepatic
cAMP content is shown in Fig. 2. Epinephrine and glucagon increased hepatic
cAMP content an average of36% and 770%, respectively, withmaximal responses 15
min after their administration. PGE1 did not significantly influence hepatic cAMP
levels compared to control infusions. DBC caused extraordinarily high cAMP levels
in the few livers analyzed, as well as in the perfusate and bile.
Figure 3 illustrates the failure of PGE1 to significantly alter hepatic TG concentra-
tion after 60 min infusion. These studies were carried out in only 6 of the 9
experiments, respectively, in the control and PGE1-treated groups.
Table 1 summarizes the increment changes observed in perfusate glucose and
cAMP and hepatic glycogen, TG and cAMP content during the 60 min period ofROBERT A. LEVINE
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FIG. 1. Effect of PGE, or Ringer-ethanol (ETOH) infusion on mean perfusate FFA, cAMP, glucose increment
change, and bile flow in isolated perfused fed rat liver. Zero time value in this and Figs. 2 and 3 represents time after 45
minute period of equilibration. Concentrations of drugs in this and Figs. 2 and 3 are given in Table 1. From Levine[21].
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FIG. 2 Effect of control infusion (Ringer-ETOH), PGEI, glucagon, and epinephrine on hepatic cAMP content
(mean ± S.E.M.) at time intervals shown in abscissa. From Levine [21].
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FIG. 3. Effect of Ringer-ETOH or PGE, infusion on mean (± S.E.M.) hepatic TG. From Levine [21].
infusion. Epinephrine, glucagon, and DBC caused significant glycemia. Glycogen
content in the liver decreased after 60 min ofperfusion incontrollivers. Thedecrease
was significantly greater when epinephrine, glucagon, or DBC was added to the
perfusate, but unchanged by PGE,.
Epinephrine-induced glycogenolysis and augmentation ofhepatic cAMP were not
affected by pretreatment or concomitant administration of PGE1, as shown in a
representative example of three such studies (Fig. 4).
The effects of PGE, or Ringer solution on certain biochemical parameters in
the fasted perfused rat liver are shown in Fig. 5. PGE, did not significantly
alter perfusate glucose or cAMP, or hepatic cAMP, glycogen, or TG as shown in
Fig. 5. Note that the perfusate cAMP concentration appeared to be greater in the
fasted than in the fed perfused liver (Fig. 1).
The effects of PGE, or Ringer solution on hepatic cAMP and cGMP concentra-
tions in fasted rat liver, as early as2,3,5,10,15 and 30 minafterthe onset ofperfusion,
are shown in Fig. 6. There was no significant difference inthe response ofthehepatic
cyclic nucleotides to either PGE, or Ringer solution. Moreover, hepatic glycogen
levels did not change significantly before and 30 min after perfusion. Mean control
liver glycogen for Ringer solution and PGEI were, respectively, 0.199 ± 0.62 and
0.170 i 0.039 mg/g before and 0.190 ± 0.073 and 0.142 ± 0.030 mg/g 30 min after
infusion. Thus, in the fasted rat liver PGEI failed to significantly alter cyclic
nucleotide, TG, and glycogen content.
The effects of both PGE, and PGE2 oncanine hepaticcyclic nucleotide concentra-
tions are shown in Fig. 7. PGE, orPGE2 failed to significantly altercyclic nucleotide
content for 30 min after the onset of arterial infusion.
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changes in perfusate cAMP
and glucose and on hepatic
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tent. From Levine [21].
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FIG. 5. Effect of PGE, and Ringer-ETOH
infusion on mean perfusate glucose and cAMP,
and mean hepatic cAMP, glycogen, and TG in the
fasted perfused liver. From Levine [21].
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FIG. 6. Effect of Ringer-ETOH or PGE, infusion on mean(± S.E.M.) hepatic cAMP and cGMP concentrations in
fasted perfused rats. As noted in the text, hepatic glycogen levels did not significantly change compared to the control
(zero time) value.
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FIG. 7. Effect of Ringer-ETOH, PGE,, or PGE2 infusion ( S.E.M.) on cAMP and cGMP concentrations infasted
intact dog liver. Thirteen experiments were performed, 7 with PGE1 and 6 with PGE2.
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Effects of PGE1, PGE2, and Indomethacin on Canine Hepatic cAMP Concentration (pmol/g)
Agent No. 0 5 10 15 30 min
PGE1 7 799* 81 893* 141 900* 195 924± 195 612t213
PGE2 6 873± 71 861 i 72 982± 193 1114 * 189 1039± 121
PGE2
+ 3 791 ± 26 879± 117 1172 i 180 590 ± 209 1046 ± 139
Indomethacin
The effects of either PGE, or PGE2 on canine hepatic cyclic AMP concentration
are shown in Table 2. Neither PGE1 or PGE2 showed a differential effect on hepatic
cAMP concentration during the 30 min perfusion. The effects of PGE2 on cGMP
concentration in 12 fasted dog livers are shown in Table 3. There were no significant
differences between the treatment periods compared to the basal period (zero time
value). Moreover, PGE2 administered in conjunction with indomethacin failed to
potentiate the action of PGE2 on liver cAMP (Table 2) or cGMP (Table 3) content.
Pretreatment with indomethacin for 30 min before the zero time showed values
essentially similar to the basal level (789 ± 62 pmol/g and 2.4 ± 0.5 pmol/g, respec-
tively, for cAMP and cGMP).
DISCUSSION
These studies indicate that PGE1 does not stimulate the rat liver adenylate cyclase-
cAMP system even though the same system responds to known agents which activate
cAMP (glucagon and epinephrine) and responds to exogenous DBC. Moreover,
cGMP is not stimulated by PGE, in the same perfusion model. In another species,
the dog, PGE, and PGE2 failed to activate hepatic cAMP or cGMP. Thus, it appears
that hepatic cyclic nucleotides fail to respond to intraportal infusion of PGEI and
PGE2.
Our findings fail to confirm the report ofZenser et al. [10] who did note transient
stimulation of rat liver cAMP after PGE1 administration. The apparently conflicting
observations may be reconciled in part by differences between their assay techniques,
which may account for spurious cAMP values, and our own. First, cross reactivity
and nonspecific reactivity producing an artificial elevation of assayable cAMP is less
common with the use of radioimmunoassay compared to. the protein binding
technique [26], as was utilized by Zenser et al. [10]. Second, pigments, including
hemoglobin, can be another source of falsely elevated assayable cyclic nucleotides.
Blood pigments are acid extractable during purification procedures. Unless great
effort is made to avoid any tissue contamination by blood prior to processing, such
pigments may significantly alter cAMP values. The use of a neutral alumina column
TABLE 3
Effect of PGE2 and Indomethacin on Canine Hepatic cGMP Concentration (pmol/g)
Agent No. 0 5 10 15 30 min
PGE2 12 4.4±0.7 4.9±0.8 4.3±0.8 4.8±0.6 4.4±0.7
PGE2
+ 4 4.0±2.3 2.6±0.5 2.6±0.8 2.3±0.6 -
Indomethacin
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in sample preparation effectively removes hemoglobin from contaminated liver
samples [26]. Zenser et al. [10] failed to employ such an alumina precolumn.
The possibility exists that continuous infusion of PGE, or PGE2 did not increase
intracellular prostaglandin levels. However, in perfused rat liver PGEI (6.7u pg/min)
increased prostaglandin concentrations in portal vein, perfusate, and liver as mea-
sured by radioimmunoassay (D.E. Wilson, personal communication). The initial
perfusate concentration was 4.9 x 10-9M before PGEl infusion, 1.9 x 10-7M during
infusion, and 6.2 x 10-8M 30 min after discontinuing PGE, administration. Thus
PGE1 infusion, which resulted in a portal vein concentration of 6.4 x 10-7M during
prostaglandin infusion, markedly increased perfusate concentrations. PGE concen-
tration in liver rose from 20.9 ± 0.8 to 1091 ± 89 pg/mg tissue and decreased to 362 ±
30 pg/mg 30 min after discontinuing the infusion. From this data, it appears that
prostaglandin infusion in rat liver is capable of increasing hepatic concentrations of
prostaglandins even though approximately 70% of the infused PGE, is metabolized
during a single passage through the liver (D.E. Wilson, personal communication).
The interaction of PGE, with catecholamines in liver was of particular interest
since prostaglandins antagonize cAMP-induced lipolysis in fat cells caused by
epinephrine [27] and inhibit hormonally-induced responses in several other tissues
[28,29]. Although PGE, was reported not to affect glucagon-stimulated increases in
hepatic cAMP in vitro, when injected intraportally PGE1 inhibited glucagon
stimulation of cAMP and stimulated cAMP itself[11]. Incontrast, our studies would
support the concept that PGE1 fails to alter the effects ofanother hepatic glycogeno-
lytic agent, epinephrine, in rat liver.
Our data do not support a physiologic role for PGE, on hepatic glycogenolysis
or lipolysis. Preliminary studies in our laboratory, using lactate as a substrate for
gluconeogenesis in the isolated perfused rat liver, have shown that PGE1 failed to
induce a greater gluconeogenic effect compared to control infusion with Ringer
solution. Glucagon, added at the same time as lactate, induced a further increased
glucose level than either a control or PGE, infusion. However, it was ofinterest that
when glucagon was given simultaneously with PGE,, there appeared to be inhibition
of the glucagon-induced hepatic gluconeogenesis. This particular observation would
support the findings of Imesch and Rous [20] and indicate that PGE, may have
inhibitory effects on hormone-mediated hepatic gluconeogenesis.
Other preliminary observations in our laboratory concerning the effects ofPGE1
on liver glycogen synthetase indicate that PGE1 and PGE2 failed to alter glycogen
synthetase ineitherfed orfasted perfused rat orfasted intact dogliver. Thesefindings
contrast with the report of Curnow and Nuttall [12], who showed a decrease in
glycogen synthetase in the fed and fasted intact rat liver 5 and 30 min, respectively,
after PGE, administration.
Although we have not yet investigated the effects of PGE, on lipogenesis,
ureogenesis, or amino acid transport, if effects are subsequently found on these
metabolic parameters they probably would occur independent of achange inhepatic
cAMP or cGMP activity. It should be pointed outthat ourconclusions are limited to
the perfused rat liver and intact dog liver. Further studies are indicated before one
can conclude that other types of prostaglandins fail to stimulate the hepatic cyclic
nucleotides in other species.
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